Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis
Journal of Clinical Oncology Feb 05, 2019
Kim C, et al. - Researchers pooled individual level data from six Canadian cancer centers of patients (pts) who received at least one cycle of chemotherapy (CT) for advanced pancreatic cancer (APC), to determine the clinical, pathologic and treatment characteristics related to long term survival (LTS). Among pts who lived < and ≥ 18 months, clinical, pathologic and treatment characteristics, as well as survival, were compared. Of overall 455 pts, metastatic disease was detected in 96% and 88 (19%) survived ≥ 18 months. Compared with pts who survived < 18 months, those with LTS demonstrated lower WBC, CA 19-9, ALP and LDH at baseline, higher albumin and BMI, better ECOG and were more likely to have tumors in the head of the pancreas, more likely to have a complete response (CR) or partial response (PR) to 1L CT, with median overall survival (mOS) 29.2 months vs 4.3 months. Primary tumor in the head of the pancreas; experiencing a CR or PR to 1L CT; and receipt of 2L doublet CT were independent predictors of LTS. ECOG ≥ 2; and elevated CA 19-9 were related to lower likelihood of LTS.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries